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Abstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 
(DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes 
(T2D). By blocking DPP-4, saxagliptin increases and prolongs the effects of incretins, a group 
of peptide hormones released by intestinal cells after meals, which stimulate glucose-dependent 
insulin secretion to lower blood glucose. In controlled clinical trials, saxagliptin adminis-
tered as monotherapy or in combination with metformin, glyburide, or a thiazolidinedione 
improved glycemic control in a clinically significant manner, reflected by significant decreases 
in glycated hemoglobin (monotherapy, −0.5%; add-on to metformin, thiazolidinedione, or 
  sulfonylurea, −0.6% to 0.9%; initial combination with metformin, −2.5%), fasting plasma 
glucose, and postprandial glucose compared with controls. Additionally, saxagliptin improved 
β-cell function, reflected as increases in homeostasis model assessment (HOMA)-2β. Saxagliptin 
was generally well tolerated; it did not increase hypoglycemia compared with controls, and 
was weight neutral. A meta-analysis of Phase II and III trials showed that saxagliptin did not 
increase the risk of major cardiovascular events. Professional organizations have updated their 
guidelines for T2D to include a DPP-4 inhibitor as an early treatment option—either as initial 
therapy in combination with metformin, or as add-on therapy for patients whose glycemia is 
inadequately controlled by a single oral antidiabetic drug.
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Introduction
Saxagliptin (Onglyza™, Bristol-Myers Squibb, Princeton, NJ; AstraZeneca Pharma-
ceuticals LP, Wilmington, DE, USA) is a selective dipeptidyl peptidase-4 (DPP-4) 
inhibitor approved for the management of type 2 diabetes (T2D) along with diet and 
exercise.1 In addition to saxagliptin, sitagliptin is currently approved in the United 
States and various regions worldwide.2 Vildagliptin is not yet approved in the United 
States.3
Structurally, saxagliptin is a cyanopyrrolidine derivative designed to provide 
extended inhibition of the DPP-4 enzyme (Figure 1).1,4,5 Saxagliptin has been 
evaluated in initial therapy of T2D both as a single agent and in combination with 
metformin,6–8 as well as add-on therapy for patients whose glycemia had not been 
adequately   controlled by metformin, a sulfonylurea (glyburide), or a thiazolidinedione 
(pioglitazone or rosiglitazone).9–11 In each treatment setting, saxagliptin significantly 
improved glycemic control relative to the comparator group, and exhibited a safety 
and tolerability profile comparable with that observed in the control arms.6–11 The 
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ment of patients with T2D. After providing the rationale for 
DPP-4 inhibition, the pharmacokinetics of   saxagliptin will 
be considered, including its use in special patient popula-
tions,   followed by the results of controlled clinical trials 
conducted with saxagliptin in the first-line and add-on 
treatment settings.
Role of incretins
The incretins are peptide hormones secreted by the intes-
tines following food consumption. They bind to specific 
G-protein–coupled receptors, thereby stimulating glucose-
  dependent insulin secretion (Figure 2).12–16 The best char-
acterized incretins are glucagon-like peptide-1 (GLP-1) 
secreted by intestinal L-cells in the distal ileum and colon, 
and   glucose-dependent insulinotropic peptide (GIP) pro-
duced by intestinal K-cells in the duodenum and jejunum. 
Together, these incretins account for approximately 50% 
to 70% of the postprandial insulin response in healthy 
individuals.13 In addition to stimulating insulin secretion, 
GLP-1 has other actions that help to control blood glucose 
levels. GLP-1 reduces postprandial glucagon secretion from 
pancreatic α-cells to lower hepatic glucose production, slows 
gastric emptying to reduce glucose absorption after meals, 
and promotes satiety to reduce further food intake.15,17
The actions of the incretins, however, are short-lived 
because they are rapidly inactivated by DPP-4, a serine 
protease that is widely distributed in human tissues, includ-
ing the intestines, pancreas, lungs, kidneys, adrenals, brain, 
and lymphocytes.13 DPP-4 predominantly cleaves peptides 
containing either an alanine or proline at position 2 of the 
N-terminus.17 The half-life (t1/2) of biologically active GLP-1 
and GIP, following exogenous administration, is ,2 and 
5–7 minutes, respectively, which reflects in part the rapid 
inactivation by DPP-4.17 The secretion of GLP-1 following 
meals is reduced modestly in patients with T2D compared 
with healthy individuals, but its actions in stimulating insulin 
secretion are preserved.17 In contrast, meal-stimulated GIP 
secretion is normal but its biologic activity is reduced in 
T2D.17 By blocking inactivation of the incretins, DPP-4 
inhibitors are designed to increase and prolong the effects 
of the incretins, particularly GLP-1, in patients with T2D, 
thereby reducing plasma glucose levels (Figure 2).12,15
DPP-4 inhibition with saxagliptin
In vitro studies have shown that saxagliptin is a highly potent, 
selective, reversible, and competitive DPP-4   inhibitor. The 
enzyme-inhibitor dissociation constant (Ki) of saxagliptin 
for DPP-4 at 37°C is 1.3 nM, making it approximately 
10-fold more potent for blocking DPP-4 than sitagliptin.18,19 
DPP-4 belongs to a family of ubiquitous atypical serine 
proteases, which have physiologic functions that go beyond 
incretin degradation to include effects on endocrine and 
immune systems.19 This family includes the intracytosolic 
members, DPP-8 and DPP-9, the specific physiologic func-
tion of which remains unclear. Saxagliptin is selective for 
DPP-4 relative to these other DPP-4 family members; the Ki 
values for   blocking DPP-8 and DPP-9 are 508 and 100 nM, 
  respectively, or approximately 400-fold and 75-fold higher 
than the   concentrations needed to block DPP-4. Moreover, 
saxagliptin displays .4000-fold higher selectivity for DPP-4 
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Figure 1 Structure of saxagliptin and 5-hydroxy saxagliptin.1,5
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Figure 2 The incretins are released from intestinal cells after a meal, and act on 
pancreatic β-cells to stimulate insulin secretion. GLP-1 also acts on pancreatic α-cells 
to inhibit glucagon secretion and thereby reduce hepatic glucose production. The 
actions of the incretins are limited by DPP-4, which rapidly degrades GLP-1 and GiP 
into inactive fragments.12–16 The presence of a DPP-4 inhibitor, such as saxagliptin, 
blocks degradation of the incretins, thereby increasing and prolonging their effects in 
the pancreas.  As a result, blood glucose is lowered.12,15 Reprinted from Gastroenterology, 
132, Baggio LL, Biology of incretins: GLP-1 and GiP,  2131–57, © 2007,16 with permission 
from the AGA institute. 
Abbreviations: GLP-1, glucagon-like peptide-1; GiP,  glucose-dependent insulinotropic 
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inhibition compared with a panel of other proteases.13,18–20 
Saxagliptin has an active metabolite (5-hydroxy   saxagliptin; 
BMS-510849) that is two-fold less active than the   parent 
drug as a DPP-4 inhibitor (Ki = 2.6 nM), but displays 
approximately two-fold greater selectivity.18,20 Saxagliptin 
dissociates slowly from the DPP-4 active site with a t1/2 of 50 
minutes, whereas slow dissociation has not been seen from 
any other enzymes tested, including DPP-8 and DPP-9.13,20 
This tight but reversible binding to DPP-4 helps to explain 
why saxagliptin provides prolonged enzyme inhibition.15 
Saxagliptin inhibited plasma DPP-4 activity in a dose-related 
manner over the dose range of 2.5–400 mg once daily in 
healthy subjects and patients with T2D. DPP-4 activity 
remained inhibited by 50% and 79% when measured at 
24 hours after the 2.5 and 400 mg doses, respectively.21 After 
an oral glucose load or meal, inhibition of the DPP-4 enzyme 
by saxagliptin resulted in a two- to three-fold increase in 
circulating levels of active GLP-1 and GIP, and increased 
glucose-dependent insulin secretion.1
The effect of saxagliptin on β-cell function was explored 
in a study of 36 treatment-naïve patients with T2D who 
received either saxagliptin 5 mg or placebo for 12 weeks.22 
Saxagliptin increased β-cell responsiveness to glucose in 
both the fasting and postprandial states, as evidenced by 
significant increases from baseline in the insulin secretion 
rate compared with placebo (P = 0.02 in the fasting state; 
P = 0.035 following oral glucose load). This was accom-
panied by a reduction in postprandial glucagon secretion. 
Moreover, saxagliptin increased and prolonged peak incretin 
levels, particularly GLP-1, after the oral glucose tolerance 
test (OGTT).22 These results indicate that saxagliptin blocks 
DPP-4, slows inactivation of the incretins, in particular 
GLP-1, and prolongs their biologic actions.1
Dosage, administration,  
and formulations
Saxagliptin is indicated as an adjunct to diet and exercise to 
improve glycemic control in adults with T2D. Saxagliptin 
should not be used in patients with type 1 diabetes or diabetic 
ketoacidosis, because the pathophysiology of these condi-
tions, as well as the drug’s mechanism of action, would not 
confer benefit in these settings.1
As indicated by the US label for saxagliptin, the rec-
ommended dose of saxagliptin for patients with T2D is 
2.5 or 5 mg orally once daily, which can be taken without 
regard to the timing of meals.1 No dosage adjustment is 
recommended based on age, gender, or race, or for patients 
with hepatic impairment or mild renal insufficiency 
(ie,   creatinine clearance [CrCl] .50 mL/min).1,23,24 How-
ever, the dose of saxagliptin should be adjusted to 2.5 mg 
for those patients with moderate-to-severe renal impair-
ment (CrCl #50 mL/min) or end-stage renal disease to 
achieve optimal saxagliptin plasma concentrations. Because 
saxagliptin is removed by hemodialysis, doses of saxagliptin 
should be given after, not before, hemodialysis sessions.1 
In addition, although dosage adjustment is not necessary 
based on age alone, it is important to recognize that elderly 
patients often have decreased renal function and, therefore, 
care should be exercised in selecting the dose of saxagliptin 
for elderly patients whose renal function may be compro-
mised.1 Dose adjustment to 2.5 mg is also recommended 
for patients who are concomitantly taking ketoconazole or 
another strong cytochrome P450 (CYP) 3A4/5 inhibitor (eg, 
atazanavir, clarithromycin, indinavir, itraconazole, nefa-
zodone, nelfinavir, ritonavir, saquinavir, or telithromycin). 
However, dosage adjustment is not necessary for patients 
taking moderate CYP 3A4/5 inhibitors, such as diltiazem, 
verapamil, erythromycin, or grapefruit juice.1
Pharmacokinetics
Absorption and exposure
The pharmacokinetics of saxagliptin were explored in two 
randomized, double-blind, placebo-controlled, sequential 
ascending-dose trials.21 The first trial evaluated saxagliptin 
at doses from 2.5 to 50 mg once daily for 14 days in 
patients with T2D; the second trial evaluated doses from 
100 to 400 mg once daily for 14 days in healthy volunteers. 
No differences in the pharmacokinetics of saxagliptin or 
5-hydroxy saxagliptin were apparent between the patients 
with T2D and healthy volunteers.21 Saxagliptin was well 
absorbed following oral administration, with time to peak 
plasma concentrations (Tmax) of saxagliptin and 5-hydroxy 
saxagliptin reached by #2 and #4 hours, respectively. 
Systemic exposure (area under the plasma concentration-
time curve [AUC]) to saxagliptin and 5-hydroxy saxagliptin 
was proportional to the saxagliptin dose over the entire 
dose range from 2.5 to 400 mg, with no substantial accu-
mulation or reduction in systemic exposure seen with the 
once-daily dosing regimen.1,21 On a molar basis, systemic 
exposure to 5-hydroxy saxagliptin was several-fold higher 
than for saxagliptin.21 For example, following a 5 mg dose, 
the mean plasma AUC values for saxagliptin and 5-hydroxy 
saxagliptin were 78 and 214 ng.h/mL, respectively.1 The 
mean t1/2 range of saxagliptin was 2.2 to 3.8 hours, and the 
t1/2 range of 5-hydroxy saxagliptin was 3.0 to 7.4 hours; both 
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70% of the administered dose was recovered in urine as the 
parent drug or 5-hydroxy saxagliptin.21
When administered with a high-fat meal, the Tmax was 
delayed by 20 minutes and was associated with a 27% 
increase in the AUC of saxagliptin compared with dosing in 
a fasted condition. These findings indicated that saxagliptin 
can be taken with or without food.25
Metabolism and elimination
Saxagliptin is eliminated by both renal and hepatic pathways. 
Following a single 50 mg dose of [14C]-saxagliptin, 24% and 
36% of the administered dose was excreted in the urine as 
saxagliptin and 5-hydroxy saxagliptin, respectively. Active 
renal secretion of saxagliptin occurs, in so far as the mean 
renal clearance of the drug (∼230 mL/min) was greater than 
the estimated glomerular filtration rate (∼120 mL/min). 
Overall, 75% of the administered radioactivity was recov-
ered in the urine and 22% in the feces, the latter representing 
the fraction of the dose excreted in bile or unabsorbed from 
the gastrointestinal tract.1
The metabolism of saxagliptin is primarily mediated 
by CYP 3A4/5 and, consequently, the coadministration of 
saxagliptin with strong CYP 3A4/5 inhibitors or inducers 
could alter the pharmacokinetics of saxagliptin and 5-hydroxy 
saxagliptin.1 When the strong CYP 3A4/5 inhibitor, keto-
conazole (200 mg at 12-hourly intervals for nine days) was 
coadministered with a single 100 mg dose of saxagliptin in 
healthy subjects, it significantly increased the time to peak 
concentration (Cmax) and AUC from zero to infinity (AUC∞) 
of saxagliptin by 62% and 145%, respectively, compared with 
administration of saxagliptin alone. Exposure to 5-hydroxy 
saxagliptin, however, was reduced by 88%.26 Based on these 
findings, reducing the dose of saxagliptin to 2.5 mg once daily 
for patients who are concomitantly taking ketoconazole or 
another strong CYP 3A4/5 inhibitor is recommended.1
Concomitant administration of long-acting diltiazem 
(360 mg once daily for nine days), a moderate CYP 3A4/5 
inhibitor, with a single 10 mg dose of saxagliptin signifi-
cantly increased the Cmax and AUC∞ of saxagliptin by 63% 
and 109%, respectively, compared with the administration of 
saxagliptin alone.27 Given the magnitude of the increase in 
exposure, dosage adjustment of saxagliptin is not needed when 
coadministered with diltiazem or other moderate CYP 3A4/5 
inhibitors.1 Coadministration of the CYP 3A4/5 substrate 
simvastatin (40 mg once daily for four days) with saxagliptin 
(10 mg once daily for four days) did not   produce a clinically 
significant effect on systemic exposure to either drug28 and, 
therefore, no dosage adjustment is needed when saxagliptin 
is given with mild CYP 3A4/5 inhibitors or substrates.27
Coadministration of metformin 1000 mg, glyburide 
5 mg, or pioglitazone 45 mg once daily for four days with 
single doses of saxagliptin revealed no clinically significant 
drug-drug interactions.29–31 Similarly, clinically significant 
interactions were not evident between saxagliptin and digoxin, 
famotidine, omeprazole, or the antacid containing alumi-
num hydroxide + magnesium hydroxide + simethicone.1,32,33 
Therefore, dosage adjustments are not needed when 
saxagliptin is coadministered with any of these agents.
Clinical trials
The efficacy and safety of saxagliptin were evaluated in a 
series of well-controlled clinical trials that enrolled treatment-
naïve patients with T2D (Table 1),6,7 or those patients unable 
to achieve or maintain glycemic   control with metformin,9 
a sulfonylurea (glyburide),10 or a   thiazolidinedione.11 
  Pregnant women, as well as children and adolescents aged 
Table 1 Summary of the effects of saxagliptin 5 mg on glycemic parameters in controlled 24-week clinical trials
Design Treatment group n Baseline  
HbA1c (%)
Mean change  
in HbA1c (%)
Patients (%)  
with HbA1c ,7%
Mean change in 
FPG (mmol/L)
Mean change 
in PPG-AUC 
(mmol∙min/L)
Monotherapy6 Saxagliptin 5 mg 106 8.0 −0.5a 38 −0.50a −2.39a
Placebo   95 7.9 0.2 24 0.33 −0.33
Add-on to MeT9 Saxagliptin 5 mg (+ MeT) 191 8.1 −0.7a 44a −1.22 −3.23
Placebo (+ MeT) 179 8.1 0.1 17 0.07 −1.00
Add-on to GLY10 Saxagliptin 5 mg (+ GLY) 253 8.5 −0.6a 23a −0.56a −1.89a
GLY up-titration  267 8.4 0.08  9 0.06 0.44
Add-on to TZD11 Saxagliptin 5 mg (+ TZD) 186 8.4 −0.9a 42 −0.10 −4.00
Placebo (+ TZD) 184 8.2 −0.3 26 −0.20 −1.00
initial therapy with  
MeT7
Saxagliptin 5 mg (+ MeT) 320 9.4 −2.5a 60a −3.33a −7.66a
MeT 328 9.4 −2.0 41 −2.61 −5.38
Note: aStatistically significant.
Abbreviations: FPG, fasting plasma glucose; GLY, glyburide; HbA1c, glycated hemoglobin; MeT, metformin; PPG, postprandial glucose; TZD, thiazolidinedione.Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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,18 years, were excluded from these trials. Saxagliptin 
carries a pregnancy category B label, reflecting that adequate 
and well-controlled trials have not been conducted in preg-
nant women. Consequently, saxagliptin, like many other 
antidiabetic medications, should be used during pregnancy 
only if clearly needed.1
Efficacy of saxagliptin monotherapy
The efficacy of saxagliptin monotherapy was initially evalu-
ated in a multicenter, randomized, double-blind, placebo-
controlled, parallel-group, dose-ranging trial conducted at 
152 US sites.8 A total of 338 treatment-naïve patients with 
T2D with inadequate glycemic control (baseline glycated 
hemoglobin [HbA1c] 6.8%–9.7%) were randomly allocated 
to treatment with saxagliptin 2.5, 5, 10, 20, or 40 mg once 
daily or placebo for 12 weeks, and an additional cohort of 
85 patients were randomized to saxagliptin 100 mg once 
daily or placebo for six weeks.8 Starting from a relatively 
low mean baseline HbA1c of 7.9%, saxagliptin at doses of 
2.5–40 mg produced consistent and clinically   significant 
HbA1c decreases of 0.72% to 0.90% compared with a 
0.27% reduction in the placebo group (P , 0.007).8 The 
placebo-  adjusted change from baseline in HbA1c ranged 
from −0.45% to −0.63%. More patients with baseline 
HbA1c $7% achieved the glycemic target of HbA1c ,7% 
with saxagliptin than with placebo (41%–53% versus 20%).8 
Comparable results were achieved in the high-dose cohort, 
in which saxagliptin 100 mg reduced HbA1c from baseline 
by 1.09% versus 0.36% for placebo, and 66% versus 22% 
of patients achieved the HbA1c target of ,7%.8 At each 
dose level, saxagliptin also reduced fasting plasma glucose 
(FPG) levels, which was first evident by the second week of 
treatment, as well as one-hour postprandial glucose (PPG) 
as part of an OGTT.8 In general, the efficacy of saxagliptin 
in reducing HbA1c and FPG was greatest in subgroups with 
higher baseline values of these glycemic parameters.8
Based on the results of the dose-ranging study, a multi-
center, randomized, double-blind, placebo-controlled Phase III 
trial was conducted to compare saxagliptin 2.5, 5, and 10 mg 
once daily versus placebo.6 A total of 401 treatment-naïve 
T2D patients with baseline HbA1c .7% to 10% were allocated 
to study treatment for 24 weeks; mean baseline HbA1c and 
FPG were 7.9% and 9.71 mmol/L, respectively.6 Saxagliptin 
produced clinically significant improvements in HbA1c and 
FPG at each dose tested. The mean changes from baseline in 
HbA1c were −0.43%, −0.46%, and −0.54% with the 2.5, 5, 
and 10 mg doses, respectively, compared with an increase of 
0.19% in the placebo group (all P , 0.0001). Similarly, the 
mean changes in FPG were −0.83, −0.50, and −0.94 mmol/L, 
respectively, compared with an increase of 0.33 mmol/L in 
the placebo group (P # 0.0074).6  The two higher saxagliptin 
doses allowed a significantly greater number of patients to 
achieve the HbA1c target of ,7% compared with placebo (38% 
and 41% versus 24%; P # 0.05), and each saxagliptin group 
had significantly greater reductions in PPG-AUC in the 75 g 
OGTT (P # 0.0002). This study also enrolled an open-label 
cohort of 68 patients with a baseline HbA1c between 10% 
and 12% who received saxagliptin 10 mg once daily for 24 
weeks.6 Saxagliptin produced greater mean improvements 
in HbA1c (−1.9%), FPG (−1.83 mmol/L), and PPG-AUC 
(−615 mmol.min/L) in this cohort than in the main study, 
consistent with their poorer glycemic status at baseline.6
Taken together, these two clinical trials demonstrated 
that saxagliptin monotherapy produced clinically significant 
improvements in glycemic control compared with placebo 
in treatment-naïve patients with T2D. The clinical benefit 
of saxagliptin was evident across a wide range of baseline 
HbA1c levels, and in general, greater HbA1c decreases 
were achieved in patients with poorer glycemic control at 
baseline.6,8
Efficacy of saxagliptin in combination 
therapy
Saxagliptin was evaluated in combination with metformin 
in two clinical trials, one evaluating add-on saxagliptin in 
patients with inadequate glycemic control on stable doses 
of metformin,9 and the other evaluating saxagliptin in com-
bination with metformin as initial therapy.7
The saxagliptin add-on trial was a randomized, double-
blind, placebo-controlled multicenter study that enrolled 743 
patients with T2D and an HbA1c of 7% to 10% despite treat-
ment with stable metformin doses from 1500 to 2550 mg/day.9 
Patients were randomly allocated to receive saxagliptin 2.5, 
5, or 10 mg once daily or placebo for 24 weeks in addition 
to continuing their stable open-label metformin dose. 
From a mean baseline HbA1c of 8.0%, add-on saxagliptin 
2.5, 5, and 10 mg significantly reduced HbA1c by −0.59%, 
−0.69%, and −0.58%, respectively, compared with an 
increase of 0.13% with add-on placebo (all P # 0.0001).9 
Clinically relevant and statistically significant reductions 
from baseline to week 24 for patients taking saxagliptin 
2.5, 5, and 10 mg in FPG (0.79, 1.22, and 1.14 mmol/L, 
respectively; all P , 0.0001) and PPG-AUC (−493, −532, 
and −452 mmol.min/L, respectively; all P , 0.0001), as well 
as in the proportion of patients achieving an HbA1c target 
,7% were achieved compared with placebo, with maximal Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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benefit seen in the saxagliptin 5 mg dose group. Patients 
receiving add-on saxagliptin had   significant increases in 
postprandial insulin compared with those receiving add-on 
placebo in the OGTT (all P , 0.0001), and in addition, 
β-cell function measured by the HOMA-2β method was 
improved in all saxagliptin treatment groups.9 Patients who 
completed the 24-week study period with or without need 
for rescue medication were eligible to enter a 42-month long-
term extension period,34 during which saxagliptin added to 
metformin provided sustained glycemic improvement. At 
102 weeks, the placebo-corrected decrease in HbA1c was 
−0.62%, −0.72%, and −0.52% with add-on saxagliptin 2.5, 
5, and 10 mg, respectively.34
The initial combination therapy trial was a multicenter, 
randomized, double-blind, 24-week study that enrolled 1306 
treatment-naïve patients with T2D and HbA1c between 8% and 
12% (mean baseline HbA1c = 9.5%).7 Patients were randomly 
allocated to one of four treatment arms: saxagliptin 5 mg + 
metformin 500 mg, saxagliptin 10 mg + metformin 500 mg, 
saxagliptin 10 mg + placebo, or metformin 500 mg + placebo. 
The dose of metformin was increased to 1000 mg after one week, 
then titrated in 500 mg increments to a maximum of 2000 mg/
day if FPG was .6.11 mmol/L. Saxagliptin was administered 
once daily, while metformin was given in two divided doses. 
Initial therapy with the saxagliptin–metformin combination 
significantly improved HbA1c, FPG, and PPG-AUC compared 
with treatment with either saxagliptin or metformin alone.7 The 
mean decrease from baseline HbA1c was 2.5% in each com-
bination group compared with reductions of 1.7% and 2.0% 
for saxagliptin or metformin alone, respectively (P , 0.0001 
versus each monotherapy). The difference in HbA1c was evident 
by week 4—the first time point assessed—and was maintained 
throughout the remainder of the treatment period. Moreover, the 
combination of saxagliptin 5 or 10 mg + metformin allowed a 
significantly greater proportion of patients to reach HbA1c targets 
,7% than either saxagliptin or metformin alone (60.3% and 
59.7% versus 32.2% and 41.1%, respectively; all P , 0.0001 
for combination versus monotherapy).7 A similar relationship 
favoring combination therapy was seen when achievement of 
HbA1c #6.5% was assessed.7 Saxagliptin 5 mg + metformin 
significantly improved FPG (−3.33 mmol/L) compared with 
metformin (−2.61 mmol/L, P = 0.0002) and saxagliptin (−1.72 
mmol/L; P , 0.0001) monotherapy, and similarly produced 
significant improvements in PPG-AUC compared with either 
agent alone (both P , 0.0001). In addition, saxagliptin–
metformin therapy produced significant improvements in 
β-cell function (based on HOMA-2β   assessment, compared 
with saxagliptin [P , 0.0001] or metformin [P # 0.0004] 
alone), numerically greater increases in postprandial insulin 
compared with metformin alone, and in early insulin response 
measured by the insulinogenic index compared with either 
agent alone.7
Add-on saxagliptin therapy was evaluated in two other 
multicenter, randomized, double-blind Phase III trials (of 
sulfonylurea [glyburide] or thiazolidinediones).10,11 In the 
glyburide add-on trial, 768 patients were enrolled who had 
inadequate glycemic control defined by HbA1c of 7.5% 
to 10% while receiving a sulfonylurea at less than the 
maximum approved dose (mean baseline HbA1c = 8.4%).10 
Patients were randomly allocated to one of three treatment 
groups using a double-dummy design, saxagliptin 2.5 mg/
day, saxagliptin 5 mg/day, or glyburide 2.5 mg/day, each 
in addition to open-label glyburide 7.5 mg/day. Blinded 
titration in the glyburide monotherapy group to a maximum 
total daily dose of 15 mg was allowed at weeks 2 and 4. 
By the end of the 24-week study, the mean total daily dose 
of glyburide was 7.4 mg in the combination therapy group 
compared with 14.6 mg in the monotherapy group, with 92% 
of patients in the glyburide monotherapy group receiving the 
maximum allowed dose of 15 mg.10 Saxagliptin + glyburide 
significantly improved HbA1c, FPG, and PPG compared 
with glyburide uptitration.10 The adjusted mean change 
from baseline in HbA1c was −0.54% and −0.64% with 
add-on saxagliptin 2.5 and 5 mg, respectively, compared 
with an increase in HbA1c of 0.08% with glyburide mono-
therapy (both P , 0.0001). The corresponding changes 
in FPG were −0.40 and −0.50 mmol/L versus +0.04 
mmol/L (P = 0.022 and P = 0.002, respectively) and in 
PPG-AUC −2 and −2 mmol⋅min/L   versus +0.44 mmol⋅min/L 
(both P , 0.0001).10 The proportion of patients reaching 
the HbA1c target of ,7% was approximately 1.5 times 
higher with add-on saxagliptin compared with glyburide 
uptitration (22.4% and 22.8% versus 9.1%; P , 0.0001).10 
The proportion reaching the more aggressive HbA1c target of 
#6.5% was also higher with add-on saxagliptin 5 mg than 
with glyburide alone (10.4% versus 4.5%; P = 0.012).
Add-on saxagliptin was also evaluated in T2D patients with 
HbA1c of 7% to 10% despite treatment with stable doses of a 
thiazolidinedione—either pioglitazone 30 or 45 mg once daily or 
rosiglitazone 4 or 8 mg once daily or 4 mg twice daily.11 In this 
study, a total of 565 patients were randomly allocated to receive 
saxagliptin 2.5 or 5 mg once daily or placebo for 24 weeks in 
addition to continuing on their stable dose of thiazolidinedione. 
Consistent with the other trials, add-on saxagliptin 2.5 and 5 mg 
significantly improved HbA1c, FPG, and PPG compared with thi-
azolidinedione alone.11 For HbA1c, the mean changes from baseline Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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were −0.66% and −0.94% with add-on saxagliptin 2.5 and 5 mg, 
respectively, compared with −0.30% with the thiazolidinedione 
alone (P = 0.0007 and P , 0.0001, respectively), and again, signifi-
cantly more patients treated with add-on saxagliptin than with a thi-
azolidinedione alone were able to achieve the HbA1c targets of ,7% 
(42.2% and 41.8% versus 25.6%, P = 0.001) and #6.5% (19.3% and 
20.7% versus 9.4%). In addition, add-on saxagliptin, particularly at 
the 5 mg dose, improved β-cell function as reflected by increases in 
HOMA-2β, and increased postprandial insulin and reduced PPG in 
the OGTT, compared with thiazolidinedione alone.11
In the latter study, each treatment group had a small 
increase in mean body weight (1.3 and 1.4 kg with add-on 
saxagliptin 2.5 or 5 mg compared with 0.9 kg with a 
thiazolidinedione alone).11 Weight gain is a well-recognized 
side effect of thiazolidinedione therapy, presumably resulting 
from fluid retention and increased adipose tissue.11 Similarly, 
in the trial with glyburide, small increases in mean body 
weight were seen in each treatment group (0.7 and 0.8 kg with 
add-on saxagliptin 2.5 or 5 mg compared with 0.3 kg with gly-
buride uptitration; P = 0.038 and P = 0.012, respectively).10 In 
comparison, saxagliptin had weight neutral effects when used 
as monotherapy,6,8 or in combination with metformin.7,9
Taken together, these trials demonstrate that saxagliptin 
added to metformin, glyburide, or a thiazolidinedione sig-
nificantly improves glycemic control in patients inadequately 
controlled by metformin, glyburide, or a thiazolidinedione 
alone (Figure 3).7,9–11
A pooled analysis of five 24-week Phase III clinical 
trials was conducted to explore the efficacy of saxaglip-
tin in elderly patients.35 In total, saxagliptin 5 mg was 
administered as monotherapy or add-on therapy to 882 
adults in these trials. Saxagliptin 5 mg produced similar 
reductions in HbA1c in patients aged $65 years as in those 
aged ,65 years. Saxagliptin produced mean changes 
from baseline HbA1c of −0.73% (compared with −0.17% 
for placebo) in the elderly cohort and −0.68% (compared 
with −0.01%) in the younger adult cohort. The tolerability 
of saxagliptin also did not differ between the younger and 
older patients.35
Safety and tolerability  
of saxagliptin
Saxagliptin was generally well tolerated whether administered 
alone or in combination with metformin, glyburide, or a 
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Figure 3 Efficacy of saxagliptin in monotherapy, add-on combination therapy, or initial combination therapy in patients with T2D. Shown are the adjusted mean changes in 
HbA1c with saxagliptin 5 mg once daily in the 24-week trials.6,7,9–11 
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thiazolidinedione. Across clinical trials, the incidence of 
adverse events in the saxagliptin 5 mg treatment arms was 
comparable with the rates in the control arms (Table 2).6,7,9–11 
In a placebo-controlled pooled safety analysis, the incidence 
of gastrointestinal adverse events was comparable in patients 
receiving saxagliptin 5 mg (18.4%) versus a comparator 
(19.1%). Furthermore, the percentage of patients receiving 
metformin as initial combination therapy with saxagliptin 
5 mg had a similar frequency of gastrointestinal adverse 
events compared with those on metformin monotherapy 
(20.1%). Patients treated with saxagliptin 5 mg plus a thi-
azolidinedione had a higher rate of edema, most commonly 
peripheral edema, than those patients who received a thiazo-
lidinedione alone (8.1% versus 4.3%).11 The higher incidence 
of edema with a pedal distribution is well recognized to 
occur when a thiazolidinedione is used in combination with 
another glucose-lowering agent.36
Hypoglycemia—when defined as events consistent 
with signs or symptoms of hypoglycemia with or without 
a   documented blood glucose level—was reported by up to 
5% of patients who received saxagliptin 5 mg alone or in 
  combination with metformin or a thiazolidinedione, and 
by nearly 15% when saxagliptin was given in   combination 
with glyburide (Table 2).6,7,9–11 These rates, however, were 
  comparable with the rates seen in the control groups. 
  Treatment with combinations that include a   sulfonylurea 
have historically been associated with increased risk 
of hypoglycemia. However, the incidence of reported 
  hypoglycemic events (14.6% versus 10.1%; P = 0.14) 
and confirmed   hypoglycemic events (0.8% versus 0.7%; 
P = 1.00) did not differ significantly between the saxagliptin 
5 mg plus glyburide and glyburide uptitration groups.10 In 
the authors’ opinion, the dose of the sulfonylurea should 
be reduced, rather than the dose of saxagliptin, in patients 
who experience hypoglycemia with the combination.10
In a pooled analysis of the three Phase III trials evaluating 
add-on saxagliptin 5 mg, the incidence of reported hypo-
glycemia was 8.3% in the saxagliptin arms compared with 
6.8% in the placebo arms.37 Less than 2.5% of the reported 
hypoglycemia episodes across all studies were confirmed by 
a fingerstick glucose level #2.78 mmol/L in association with 
symptoms (Table 2). Even when higher doses of saxagliptin 
were included in the analysis, the incidence of confirmed 
hypoglycemia remained infrequent in both younger adults 
and elderly patients.37 In the long-term extension study, 
adding saxagliptin 5 mg to metformin did not increase the 
incidence of reported hypoglycemia compared with adding 
placebo to metformin (8.9% versus 10.1%), and confirmed 
hypoglycemia was rare in both groups (#1.1%).34 These 
findings show that saxagliptin used as monotherapy or 
in combination therapy has a low propensity for causing 
hypoglycemia in patients with T2D.37
In late 2008, the US Food and Drug Administration 
(FDA) issued guidance recommendations for demonstrating 
that an investigational antidiabetic agent for T2D is not asso-
ciated with unacceptable increases in cardiovascular risk.38 
Table 2 incidence of common adverse events and hypoglycemia in controlled 24-week clinical trials with saxagliptin 5 mg
Monotherapy6 Add-on to MET9 Add-on to GLY10 Add-on to TZD11 Initial combination  
with MET7
SAXA  
5 mg
Placebo SAXA  
5 mg 
(+MET)
Placebo  
(+MET)
SAXA  
5 mg 
(+GLY)
Placebo  
+UP-GLY
SAXA  
5 mg  
(+TZD)
Placebo  
(+TZD)
SAXA  
5 mg 
(+MET)
MET
Adverse event, n (%)
n 106 95 191 179 253 267 186 184 320 328
Headache 10 (9.4) 7 (7.4) 11 (5.8) 13 (7.3) 19 (7.5) 15 (5.6) 10 (5.4) 7 (3.8) 24 (7.5) 17 (5.2)
Back pain 7 (6.6) 5 (5.3) 5 (2.6) 12 (6.7) 15 (5.9) 12 (4.5) – – – –
Diarrhea 1 (0.9) 3 (3.2) 11 (5.8) 20 (11.2) 10 (4.0) 16 (6.0) – – 22 (6.9) 24 (7.3)
Hypertension – – 4 (2.1) 6 (3.4) 16 (6.3) 6 (2.2) 8 (4.3) 9 (4.9) 15 (4.7) 11 (3.4)
Peripheral edema – – – – – – 15 (8.1) 8 (4.3) – –
infections
  URTi 9 (8.5) 11 (11.6) 9 (4.7) 9 (5.0) 16 (6.3) 18 (6.7) 17 (9.1) 13 (7.1) – –
  UTi 9 (8.5) 4 (4.2) 10 (5.2) 8 (4.5) 27 (10.7) 22 (8.2) 12 (6.5) 12 (6.5) – –
  Nasopharyngitis 6 (5.7) 6 (6.3) 13 (6.8) 14 (7.8) 15 (5.9) 18 (6.7) 9 (4.8) 11 (6.0) 22 (6.9) 13 (4.0)
Hypoglycemia
  Reported casesa 5 (4.7) 6 (6.3) 10 (5.2) 9 (5.0) 37 (14.6) 27 (10.1) 5 (2.7) 7 (3.8) 11 (3.4) 13 (4.0)
  Confirmed casesb 0 (0) 0 (0) 1 (0.5) 1 (0.6) 2 (0.8) 2 (0.7) 0 (0) 0 (0) 0 (0) 1 (0.3)
A dash (–) indicates that the incidence was not reported. aReported hypoglycemia was defined as events consistent with signs or symptoms of hypoglycemia with or without 
documented blood glucose levels. bConfirmed hypoglycemia was defined by a fingerstick glucose value of #2.78 mmol/L with associated symptoms.
Abbreviations: GLY, glyburide; MeT, metformin; PBO, placebo; SAXA, saxagliptin; TZD, thiazolidinedione; UP-GLY, uptitrated glyburide; URTi, upper respiratory tract 
infection; UTi, urinary tract infection.Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Specifically, a meta-analysis of important   cardiovascular 
events should be conducted across Phase II and Phase III 
controlled clinical trials, and if possible, it should also 
explore similarities and differences among subgroups.38 
Saxagliptin met this FDA recommendation in a post hoc 
analysis.38 The meta-analysis included 4607 patients, of 
whom 3356 were exposed to saxagliptin (including 1269 to 
the 5 mg dose) and 1251 to control treatment.39 This dataset 
included 3758 patient-years of exposure to saxagliptin. Over-
all, the incidence of major cardiovascular events (MACE), 
consisting of cardiovascular death, nonfatal myocardial 
infarction, and nonfatal stroke, was 0.7% among patients 
treated with saxagliptin (0.5% for those who received the 
5 mg dose) compared with 1.4% for patients who received 
control treatment (hazard ratio 0.44; 95% confidence interval 
0.24–0.82). Moreover, the incidence of MACE was lower 
with saxagliptin than controls in most subgroups considered 
to be at increased cardiovascular risk, including patients 
with a history of cardiovascular disease, patients with at 
least one cardiovascular risk factor besides T2D, patients 
with a history of hypertension or hypercholesterolemia, and 
male patients. This meta-analysis showed no evidence of 
increased cardiovascular risk in patients with T2D exposed 
to saxagliptin for up to 2.5 years.39 A prospective outcomes 
trial to evaluate whether or not saxagliptin may have a 
cardioprotective effect is currently underway.40
Guideline recommendations  
for DPP-4 inhibitors
The American Association of Clinical Endocrinologists 
and American College of Endocrinology recommend a 
glycemic target (HbA1c) of 6.5%.41 Similarly, the Asociación 
  Latinoamericana de Diabetes defines an appropriate HbA1c 
level as ,6.5%.42 According to the American Association 
of Clinical Endocrinologists/American College of Endo-
crinology algorithm, the treatment approach should be 
stratified based on the current HbA1c.41 Monotherapy may 
be used initially for patients with HbA1c #7.5%, and if not 
sufficient to achieve the glycemic target, then an additional 
medication (ie, add-on therapy) is recommended. For 
patients with HbA1c of 7.6% to 9.0%, combination therapy 
with two antidiabetic agents should be initiated, because no 
single agent is likely to achieve the target glycemic control 
level. Metformin is recommended as the cornerstone of 
therapy, or if   contraindicated due to renal or hepatic disease, 
gastrointestinal intolerance, or risk of lactic acidosis, a thi-
azolidinedione may be used.41 Because these agents serve 
as insulin sensitizers, DPP-4 inhibitors are an appropriate 
option for use as the second agent in dual-therapy regimens. 
For asymptomatic patients with HbA1c .9.0%, triple therapy 
may be initiated, such as metformin, a DPP-4 inhibitor, and 
either a sulfonylurea or thiazolidinedione.41
The American Diabetes Association and European 
  Association for the Study of Diabetes recommend an HbA1c 
target of ,7%.43 Metformin is also the cornerstone of 
treatment in the American Diabetes Association/European 
Association for the Study of Diabetes algorithm, but either 
a sulfonylurea or insulin is suggested for add-on therapy, 
with the latter recommended for patients with HbA1c .8.5%. 
DPP-4 inhibitors, like several other antidiabetic drug classes 
are not listed in the treatment algorithm, but are recog-
nized to be an appropriate choice for selected patients.43 
The Asociación Latinoamericana de Diabetes has set a more 
aggressive target for glycemic control in patients with T2D. 
The Asociación Latinoamericana de Diabetes guidelines 
recommend an HbA1c of ,6%, FPG ,5.56 mmol/L, and a 
one- to two-hour PPG ,7.78 mmol·min/L.42
Conclusions
Multiple classes of oral antidiabetic agents are available for 
managing T2D. Although improved glycemic control may 
be achieved initially, the efficacy of these agents may dimin-
ish over time due in part to increasing β-cell dysfunction 
that occurs with disease progression.13 Traditionally, T2D 
was managed with metformin, sulfonylureas, and insulin, 
but surveys indicated that many patients fail to achieve 
recommended HbA1c targets. Despite increased awareness 
about the importance of tight glycemic control, as well as 
the availability of several new antidiabetic agents, surveys 
continue to show that many patients are still not at recom-
mended glycemic targets. In Brazil, a recent survey found 
that only 23% of patients with T2D had achieved an HbA1c 
,7%.44 Higher glycemic control rates were reported in the 
National Health and Nutrition Examination Surveys con-
ducted in 1999–2002 and 2003–2004 in the United States 
but still .40% of patients with T2D had not achieved an 
HbA1c ,7%, even though many reported that they were tak-
ing either oral hypoglycemic drugs or insulin.45,46
With the evolution of  T2D management, treatment guide-
lines issued by professional organizations are being updated to 
include the use of DPP-4 inhibitors (as discussed above).41,42 
Like other DPP-4 inhibitors, saxagliptin is effective, well 
tolerated, and can be administered orally once daily with or 
without food.1 As shown across multiple controlled clini-
cal trials, saxagliptin, in particular, is effective in reducing 
HbA1c, FPG, and PPG, whether used as monotherapy or in Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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combination with other oral agents, including metformin, 
  sulfonylureas, and thiazolidinediones. Moreover, saxagliptin 
and other DPP-4 inhibitors offer an attractive safety and 
tolerability profile, with a low risk of hypoglycemia and gas-
trointestinal intolerance when added on to existing therapy, 
compared with a glinide or sulfonylurea.7,9–11,41,43 Saxagliptin 
is weight neutral and also has a beneficial effect on β-cell 
function.22,43 Taken together, the efficacy, safety, and toler-
ability of saxagliptin combined with the convenience of 
once-daily dosing makes it an attractive agent for use in the 
management of T2D.
Disclosure
Dr Antonio R Chacra has received research grants from Eli 
Lilly, MSD, Novartis, Novo Nordisk, Bristol-Myers Squibb, 
AstraZeneca, and sanofi-aventis. He is a member of the 
Brazilian Bristol-Myers Squibb/AstraZeneca Saxagliptin 
Board and has received honorarium fees for lecturing on 
saxagliptin. Technical and editorial assistance was provided 
by Gina Coviello, MS, Quintiles Medical Communications, 
Parsippany, NJ, USA.
References
  1.  Onglyza [package insert]. Princeton, NJ/Wilmington, DE: Bristol-
Myers Squibb Company/AstraZeneca Pharmaceuticals LP; Jul 2009.
  2.  Januvia [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; 
Feb 2010.
  3.  Galvus [European Public Assessment Report]. West Sussex, UK: 
  Novartis Europharm Limited. Available from: http://www.ema.europa.
eu/  humandocs/Humans/EPAR/galvus/galvus.htm. Accessed Jun 8, 
2010.
  4.  Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical 
profile of Saxagliptin (BMS-477118): A highly potent, long-acting, 
orally active dipeptidyl peptidase IV inhibitor for the treatment of type 
2 diabetes. J Med Chem. 2005;48(15):5025–5037.
  5.  Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl 
peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical 
projections. Drug Metab Dispos. 2009;37(6):1164–1171.
  6.  Rosenstock J, Aguilar-Salinas C, Klein E; CV181-011 Study   Investigators. 
Effect of saxagliptin monotherapy in treatment-naive patients with 
type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411.
  7.  Jadzinsky M, Pfützner A, Paz-Pacheco E; CV181-039 Investigators. 
Saxagliptin given in combination with metformin as initial therapy 
improves glycemic control in patients with type 2 diabetes compared 
with either monotherapy: A randomized controlled trial. Diabetes Obes 
Metab. 2009;11(6):611–622.
  8.  Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the 
dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with 
type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–386.
  9.  DeFronzo RA, Hissa M, Garber AJ, et al; Saxagliptin 014 Study Group. 
The efficacy and safety of saxagliptin when added to metformin therapy 
in patients with inadequately controlled type 2 diabetes on metformin 
alone. Diabetes Care. 2009;32(9):1649–1655.
  10.  Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. 
Saxagliptin added to a submaximal dose of sulphonylurea improves 
glycaemic control compared with uptitration of sulphonylurea in 
patients with type 2 diabetes: A randomised controlled trial. Int J Clin 
Pract. 2009;63(9):1395–1406.
  11. Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. 
Saxagliptin added to a thiazolidinedione improves glycemic control 
in patients with type 2 diabetes and inadequate control on thiazolidin-
edione alone. J Clin Endocrinol Metab. 2009;94(12):4810–4819.
  12.  Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3): 
153–165.
  13.  Tahrani AA, Piya MK, Barnett AH. Saxagliptin: A new DPP-4 inhibitor 
for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26(3): 
249–262.
  14.  Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, 
Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, 
sustains insulin levels, and reduces glucagon levels in type 2 diabetes. 
J Clin Endocrinol Metab. 2004;89(5):2078–2084.
  15.  Barnett A. DPP-4 inhibitors and their potential role in the management 
of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454–1470.
  16.  Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. 
  Gastroenterology. 2007;132(6):2131–2157.
  17.  Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin 
Invest. 2007;117(1):24–32.
  18.  Kirby MS, Dorso C, Wang A, et al. In vitro enzymologic characteris-
tics of saxagliptin, a highly potent and selective DPP4 inhibitor with 
‘slow binding’ characteristics. Abstract presented at: 3rd International 
Conference on Dipeptidyl Peptidase and Related Proteins. 2008 Apr 
23–25; Antwerp, Belgium.
  19.  Kirby M, Yu DM, O’Connor S, Gorrell MD. Inhibitor selectivity in 
the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 
(Lond). 2010;118(1):31–41.
  20.  Wang A, Dorso C, Kopcho L, Marcinkeviciene J, Kirby MS. 
Implications of the prolonged dissociation rate of saxagliptin, a 
highly potent and selective DPP4 inhibitor, on plasma DPP mea-
surements [ADA Abstr 2088-PO]. Diabetes. 2008;57 Suppl 1: 
A576–A577.
  21.  Boulton D, Geraldes M. Safety, tolerability, pharmacokinetics and phar-
macodynamics of once-daily oral doses of saxagliptin for 2 weeks in 
type 2 diabetic and healthy subjects. Diabetes. 2009;56 Suppl 1:606P.
  22.  Henry R, Smith S, Schwartz S, List JF, Duan Y, Chen R. β-cell 
  stimulation by saxagliptin in patients with type 2 diabetes. Diabetes. 
2009;58 Suppl 1:A119.
  23.  Boulton D, Goyal A, Li L, Kornhauser D, Frevert E. The effects of 
age and gender on the single-dose pharmacokinetics and safety of 
saxagliptin in healthy subjects [ADA Abstr 551-P]. Diabetes. 2008; 
57 Suppl 1:A165.
  24.  Patel C, Castaneda L, Frevert U, Li L, Kornhauser DM, Boulton DW. 
Single-dose pharmacokinetics and safety of saxagliptin in subjects 
with hepatic impairment compared with healthy subjects [ADA Abstr 
537-P]. Diabetes. 2008;57 Suppl 1:A160.
  25.  Patel CG, Zhang J, Li L, et al. Effect of a high-fat meal on the 
pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol. 
2010 Feb 11 [Epub ahead of print].
  26.  Patel CG, Boulton DW, Brenner E, Royzman K, Li L. Effect of keto-
conazole on the pharmacokinetics of saxagliptin in healthy subjects. 
J Clin Pharmacol. 2007;47:Abstr 89.
  27.  Girgis S, Patel C, Li L, et al. Effect of diltiazem on the   pharmacokinetics 
of saxagliptin in healthy subjects. J Clin Pharmacol. 2007;47:Abstr 72.
  28.  Girgis S, You X, Li L, Maurer C, Whigan D, Boulton DW. Effect of 
simvastatin on the pharmacokinetics of saxagliptin in healthy subjects. 
J Clin Pharmacol. 2007;47:Abstr 28.
  29.  Patel CG, Wolf RA, Komoroski B, Li L, Boulton DW. No meaningful 
pharmacokinetic drug-drug interaction between saxagliptin and piogli-
tazone in healthy subjects. Poster presented at: The American College 
of Clinical Pharmacy Annual Meeting. 2007 Oct 14–17; Denver, CO. 
Abstr 226.
  30.  Patel CG, Komoroski B, Li L, Boulton DW. No meaningful 
  pharmacokinetic drug-drug interaction between saxagliptin and 
  glyburide in healthy subjects. Poster presented at: The American Col-
lege of Clinical Pharmacy Annual Meeting. 2007 Oct 14–17; Denver, 
CO. Abstr 212.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is 
an international, peer-reviewed open-access journal committed to 
the rapid publication of the latest laboratory and clinical findings 
in the fields of diabetes, metabolic syndrome and obesity research.   
Original research, review, case reports, hypothesis formation, expert 
opinion and commentaries are all considered for publication. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
335
Saxagliptin for type 2 diabetes
  31.  Patel CG, Komoroski B, Brenner E, Li L, Boulton DW. No meaningful 
pharmacokinetic drug-drug interactions between saxagliptin and met-
formin in healthy subjects. Poster presented at: The American College of 
Clinical Pharmacy (ACCP). 2007 Oct 14–17; Denver, CO. Abstr 213.
  32.  Boulton DW, Li L, Patel CG. No pharmacokinetic interaction between 
saxagliptin and digoxin in healthy subjects [Abstr PIII-69]. Clin 
  Pharmacol Ther. 2008;83 Suppl 1:S93.
  33.  Boulton DW, Adams D, Li L, et al. Maalox® Max, famotidine or   omeprazole 
do not meaningfully affect the pharmacokinetics of saxagliptin in healthy 
subjects. Clin Pharmacol Ther. 2008;83 Suppl 1:S92.
  34.  DeFronzo R, Hissa MN, Garber AJ, Duan RY, Ravichandran S, Chen R. 
Once-daily saxagliptin added to metformin provides sustained glycemic 
control and is well tolerated over 102 weeks in patients with type 2 
diabetes [ADA Abstr 547-P]. Diabetes. 2009;58 Suppl 1:A147.
  35.  Maheux P, Doucet J, Allen E, et al. Efficacy and safety of saxagliptin 
5 mg once-daily therapy in elderly patients with type 2 diabetes mel-
litus [EASD Abstr 766-P]. Diabetologia. 2009;52 Suppl 1:S302.
  36.  Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid 
retention, and congestive heart failure: A consensus statement from 
the American Heart Association and American Diabetes Association. 
Diabetes Care. 2004;27(1):256–263.
  37.  Chen R, Donovan M, Rusnak JM. Saxagliptin used as monotherapy or in 
combination with other antihyperglycemic agents does not significantly 
increase risk of hypoglycemia [ADA Abstr 2082-PO]. Diabetes. 2009;58 
Suppl 1:A536.
  38.  US Food and Drug Administration. Guidance for industry: Diabetes 
mellitus – evaluating cardiovascular risk in new antidiabetic therapies 
to treat type 2 diabetes. Silver Spring, MD: Center for Drug Evaluation 
and Research; Dec 2008.
  39.  Frederich R, Alexander TH, Fiedorek FT, et al. A systematic assessment 
of cardiovascular outcomes in the saxagliptin drug development 
program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27.
  40.  Bristol-Myers Squibb/AstraZeneca. Does saxagliptin reduce the risk of 
cardiovascular events when used alone or added to other diabetes medi-
cations (SAVOR- TIMI 53). In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US), 2010 [cited 2010 May 4]. 
Available from: http://clinicaltrials.gov/ct2/show/NCT01107886 NLM 
Identifier: NCT01107886. Accessed on Jun 30, 2010.
  41.  Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an 
American Association of Clinical Endocrinologists/American Col-
lege of Endocrinology consensus panel on type 2 diabetes mel-
litus: An algorithm for glycemic control. Endocr Pract. 2009;15(6): 
541–559.
  42.  Asociación Latinoamericana de Diabetes. Guías ALAD de diagnós-
tico control y tratamiento de la diabetes mellitus tipo 2. Available 
from: http://www.sld.cu/galerias/pdf/sitios/diabetes/guias_alad_
de_diagnostico_y_tratamiento_de_la_diadetes_tipo_2(2006).pdf. 
Accessed on Mar 25, 2010.
  43.  Nathan DM, Buse JB, Davidson MB, et al. Medical management of 
hyperglycemia in type 2 diabetes: A consensus algorithm for the initia-
tion and adjustment of therapy: A consensus statement of the American 
Diabetes Association and the European Association for the Study of 
Diabetes. Diabetes Care. 2009;32(1):193–203.
  44.  Mendes AB, Fittipaldi JA, Neves RC, Chacra AR, Moreira ED Jr. 
Prevalence and correlates of inadequate glycaemic control: Results 
from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta 
Diabetol. 2010;47(2):137–145.
  45. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of 
American Diabetes Association clinical practice recommendations 
among US adults with diabetes, 1999–2002: The National Health 
and Nutrition Examination Survey. Diabetes Care. 2006;29(3): 
531–537.
  46.  Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control 
improving in US adults? Diabetes Care. 2008;31(1):81–86.